[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fJeEp2BdrySHUJnStBGlioKakp6tG4k9rOmwv0mGOL-8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":74,"rows":81},"St. Joseph's Healthcare Hamilton",[4],141,false,31,16,1005966,8,102,[14,17,20,22,25,27,29,31],{"name":15,"count":16},"Lung Cancer",7,{"name":18,"count":19},"Depression",5,{"name":21,"count":19},"Non-small Cell Lung Cancer",{"name":23,"count":24},"Perinatal Anxiety",4,{"name":26,"count":24},"Non Small Cell Lung Cancer",{"name":28,"count":24},"Asthma",{"name":30,"count":24},"Major Depressive Disorder",{"name":32,"count":33},"Obesity",3,[35,40,45,50,55,60,65,70],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT06498440","Efficacy of NSAID vs. Steroid-NSAID Combo Post-Selective Laser Trabeculoplasty: Phase 4, Single-Center RCT","2025-07-01","Ketorolac 0.5% Eye Drops",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT04478305","Affect of Duavive on Mood & Anxiety Symptoms","2025-12","Duavive 0.45Mg-20Mg",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT06680245","Effect of Mitomycin-C on the Outcomes of Patients Receiving Ahmed Glaucoma Valve Implantation Surgery","2026-07-01","Mitomycin c",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT03953144","Synapse 3D With Intravascular Indocyanine Green","2026-09-30","IC-Green",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT02570815","Near-Infrared Fluorescence Guided Robotic Pulmonary Segmentectomy for Early Stage Lung Cancer","2026-10","indocyanine green",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT06966206","Multiprofen-CC to Reduce Pain in Hand Arthritis","2026-12-31","Multiprofen-CC™ plus standard treatment",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT06251375","Early Sedation With Dexmedetomidine vs. Placebo in Older Ventilated Critically Ill Patients","2027-12-31","Dexmedetomidine",{"nctId":71,"briefTitle":72,"date":73,"intervention":69},"NCT06259565","Non-invasive Ventilation and Dexmedetomidine in Critically Ill Adults","2029-12-31",[75,76,77,78,79,80],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[82,126,150,168,190,212,233,265,289,323,348,374,392,417,444,462,488,506,524,561,586,604,629,655,673,701,719,737,766,784,813,831,857,883,908,931,955,983,1001,1024,1049,1075,1103,1129,1147,1175,1193,1211,1229,1253],{"intervention":69,"totalTrials":33,"cells":83},{"EARLY_PHASE1":84,"PHASE1":87,"PHASE2":89,"PHASE3":91,"PHASE4":114,"NA":124},{"trials":85,"activeCount":86},[],0,{"trials":88,"activeCount":86},[],{"trials":90,"activeCount":86},[],{"trials":92,"activeCount":113,"soonestReadout":73},[93,102],{"nctId":71,"briefTitle":72,"status":94,"phases":95,"primaryCompletion":73,"completion":96,"start":97,"enrollment":98,"conditions":99,"interventions":101},"RECRUITING",[78],"2030-01-31","2025-07-29",846,[100],"Non-Invasive Ventilation",[69],{"nctId":103,"briefTitle":104,"status":105,"phases":106,"primaryCompletion":107,"completion":107,"start":108,"enrollment":109,"conditions":110,"interventions":112},"NCT04878510","Non-invasive Ventilation and Dex in Critically Ill Adults","COMPLETED",[78],"2024-04-21","2022-03-07",24,[111],"Respiratory Insufficiency",[69],1,{"trials":115,"activeCount":113,"soonestReadout":68},[116],{"nctId":66,"briefTitle":67,"status":117,"phases":118,"primaryCompletion":68,"completion":119,"start":120,"enrollment":121,"conditions":122,"interventions":123},"NOT_YET_RECRUITING",[79],"2028-01-31","2025-09-07",300,[111],[69],{"trials":125,"activeCount":86},[],{"intervention":39,"totalTrials":113,"cells":127},{"EARLY_PHASE1":128,"PHASE1":130,"PHASE2":132,"PHASE3":134,"PHASE4":136,"NA":148},{"trials":129,"activeCount":86},[],{"trials":131,"activeCount":86},[],{"trials":133,"activeCount":86},[],{"trials":135,"activeCount":86},[],{"trials":137,"activeCount":113,"soonestReadout":38},[138],{"nctId":36,"briefTitle":37,"status":117,"phases":139,"primaryCompletion":38,"completion":38,"start":140,"enrollment":141,"conditions":142,"interventions":146},[79],"2024-09-01",126,[143,144,145],"Open Angle Glaucoma","Ocular Hypertension","Postoperative Inflammation",[39,147],"Ketorolac 0.5% and Fluorometholone 0.1% Eye Drops",{"trials":149,"activeCount":86},[],{"intervention":147,"totalTrials":113,"cells":151},{"EARLY_PHASE1":152,"PHASE1":154,"PHASE2":156,"PHASE3":158,"PHASE4":160,"NA":166},{"trials":153,"activeCount":86},[],{"trials":155,"activeCount":86},[],{"trials":157,"activeCount":86},[],{"trials":159,"activeCount":86},[],{"trials":161,"activeCount":113,"soonestReadout":38},[162],{"nctId":36,"briefTitle":37,"status":117,"phases":163,"primaryCompletion":38,"completion":38,"start":140,"enrollment":141,"conditions":164,"interventions":165},[79],[143,144,145],[39,147],{"trials":167,"activeCount":86},[],{"intervention":49,"totalTrials":113,"cells":169},{"EARLY_PHASE1":170,"PHASE1":172,"PHASE2":174,"PHASE3":176,"PHASE4":186,"NA":188},{"trials":171,"activeCount":86},[],{"trials":173,"activeCount":86},[],{"trials":175,"activeCount":86},[],{"trials":177,"activeCount":113,"soonestReadout":48},[178],{"nctId":46,"briefTitle":47,"status":117,"phases":179,"primaryCompletion":48,"completion":180,"start":181,"enrollment":182,"conditions":183,"interventions":185},[78],"2026-12-01","2024-12-01",144,[184],"Glaucoma",[49],{"trials":187,"activeCount":86},[],{"trials":189,"activeCount":86},[],{"intervention":64,"totalTrials":113,"cells":191},{"EARLY_PHASE1":192,"PHASE1":194,"PHASE2":196,"PHASE3":198,"PHASE4":208,"NA":210},{"trials":193,"activeCount":86},[],{"trials":195,"activeCount":86},[],{"trials":197,"activeCount":86},[],{"trials":199,"activeCount":113,"soonestReadout":63},[200],{"nctId":61,"briefTitle":62,"status":94,"phases":201,"primaryCompletion":63,"completion":202,"start":203,"enrollment":204,"conditions":205,"interventions":207},[78],"2027-08-01","2026-03-09",42,[206],"Hand Osteoarthritis",[64],{"trials":209,"activeCount":86},[],{"trials":211,"activeCount":86},[],{"intervention":54,"totalTrials":113,"cells":213},{"EARLY_PHASE1":214,"PHASE1":216,"PHASE2":218,"PHASE3":227,"PHASE4":229,"NA":231},{"trials":215,"activeCount":86},[],{"trials":217,"activeCount":86},[],{"trials":219,"activeCount":113,"soonestReadout":53},[220],{"nctId":51,"briefTitle":52,"status":94,"phases":221,"primaryCompletion":53,"completion":63,"start":222,"enrollment":223,"conditions":224,"interventions":226},[76,77],"2022-12-01",32,[21,225],"Primary Neoplasm",[54],{"trials":228,"activeCount":86},[],{"trials":230,"activeCount":86},[],{"trials":232,"activeCount":86},[],{"intervention":234,"totalTrials":235,"cells":236},"Indocyanine Green",2,{"EARLY_PHASE1":237,"PHASE1":239,"PHASE2":257,"PHASE3":259,"PHASE4":261,"NA":263},{"trials":238,"activeCount":86},[],{"trials":240,"activeCount":113,"soonestReadout":58},[241,250],{"nctId":242,"briefTitle":243,"status":244,"phases":245,"primaryCompletion":246,"completion":246,"start":246,"enrollment":86,"conditions":247,"interventions":249},"NCT02570958","ENB Robotic ICG Guided Surgery: A Novel Technique for Targeting Small Lung Tumors","WITHDRAWN",[76],"2017-10",[21,248],"Thoracic Surgery",[234],{"nctId":56,"briefTitle":57,"status":94,"phases":251,"primaryCompletion":58,"completion":252,"start":253,"enrollment":254,"conditions":255,"interventions":256},[76],"2026-12","2016-10",250,[21],[59],{"trials":258,"activeCount":86},[],{"trials":260,"activeCount":86},[],{"trials":262,"activeCount":86},[],{"trials":264,"activeCount":86},[],{"intervention":44,"totalTrials":113,"cells":266},{"EARLY_PHASE1":267,"PHASE1":269,"PHASE2":281,"PHASE3":283,"PHASE4":285,"NA":287},{"trials":268,"activeCount":86},[],{"trials":270,"activeCount":113,"soonestReadout":43},[271],{"nctId":41,"briefTitle":42,"status":94,"phases":272,"primaryCompletion":43,"completion":43,"start":273,"enrollment":274,"conditions":275,"interventions":280},[76],"2024-07-03",30,[276,277,278,279],"Menopause","Depression, Anxiety","Sleep","Menopause Related Conditions",[44],{"trials":282,"activeCount":86},[],{"trials":284,"activeCount":86},[],{"trials":286,"activeCount":86},[],{"trials":288,"activeCount":86},[],{"intervention":290,"totalTrials":235,"cells":291},"Contrave 8Mg-90Mg Extended-Release",{"EARLY_PHASE1":292,"PHASE1":294,"PHASE2":296,"PHASE3":298,"PHASE4":300,"NA":321},{"trials":293,"activeCount":86},[],{"trials":295,"activeCount":86},[],{"trials":297,"activeCount":86},[],{"trials":299,"activeCount":86},[],{"trials":301,"activeCount":86},[302,313],{"nctId":303,"briefTitle":304,"status":305,"phases":306,"primaryCompletion":307,"completion":308,"start":309,"enrollment":310,"conditions":311,"interventions":312},"NCT04587843","A Trial Evaluating the Effectiveness of Contrave in Patients Who Have Weight Recidivism Following Bariatric Surgery","UNKNOWN",[79],"2023-12-30","2023-12-31","2021-04-01",18,[32],[290],{"nctId":314,"briefTitle":315,"status":305,"phases":316,"primaryCompletion":308,"completion":308,"start":317,"enrollment":318,"conditions":319,"interventions":320},"NCT04589130","Evaluating Contrave for Weight Maintenance in Adults With BMI >= 27 Kg\u002Fm2, After 6 Month Behaviour Modification Program.",[79],"2021-02-01",89,[32],[290],{"trials":322,"activeCount":86},[],{"intervention":324,"totalTrials":113,"cells":325},"fluticasone 25, 50, 100, 200 mcg",{"EARLY_PHASE1":326,"PHASE1":328,"PHASE2":330,"PHASE3":332,"PHASE4":334,"NA":346},{"trials":327,"activeCount":86},[],{"trials":329,"activeCount":86},[],{"trials":331,"activeCount":86},[],{"trials":333,"activeCount":86},[],{"trials":335,"activeCount":86},[336],{"nctId":337,"briefTitle":338,"status":105,"phases":339,"primaryCompletion":340,"completion":340,"start":341,"enrollment":342,"conditions":343,"interventions":345},"NCT00292838","Relative Potency of Inhaled Corticosteroids",[79],"2007-02","2001-01",40,[28,344],"Chronic Obstructive Pulmonary Disease (COPD)",[324],{"trials":347,"activeCount":86},[],{"intervention":349,"totalTrials":113,"cells":350},"Midazolam",{"EARLY_PHASE1":351,"PHASE1":353,"PHASE2":355,"PHASE3":357,"PHASE4":359,"NA":372},{"trials":352,"activeCount":86},[],{"trials":354,"activeCount":86},[],{"trials":356,"activeCount":86},[],{"trials":358,"activeCount":86},[],{"trials":360,"activeCount":86},[361],{"nctId":362,"briefTitle":363,"status":105,"phases":364,"primaryCompletion":365,"completion":365,"start":366,"enrollment":367,"conditions":368,"interventions":370},"NCT01514695","Fentanyl Use for Sedation in Esophagogastroduodenoscopy",[79],"2012-12","2012-02",139,[369],"Endoscopy",[349,371],"Fentanyl",{"trials":373,"activeCount":86},[],{"intervention":371,"totalTrials":113,"cells":375},{"EARLY_PHASE1":376,"PHASE1":378,"PHASE2":380,"PHASE3":382,"PHASE4":384,"NA":390},{"trials":377,"activeCount":86},[],{"trials":379,"activeCount":86},[],{"trials":381,"activeCount":86},[],{"trials":383,"activeCount":86},[],{"trials":385,"activeCount":86},[386],{"nctId":362,"briefTitle":363,"status":105,"phases":387,"primaryCompletion":365,"completion":365,"start":366,"enrollment":367,"conditions":388,"interventions":389},[79],[369],[349,371],{"trials":391,"activeCount":86},[],{"intervention":393,"totalTrials":113,"cells":394},"Rivaroxaban",{"EARLY_PHASE1":395,"PHASE1":397,"PHASE2":399,"PHASE3":401,"PHASE4":403,"NA":415},{"trials":396,"activeCount":86},[],{"trials":398,"activeCount":86},[],{"trials":400,"activeCount":86},[],{"trials":402,"activeCount":86},[],{"trials":404,"activeCount":86},[405],{"nctId":406,"briefTitle":407,"status":105,"phases":408,"primaryCompletion":409,"completion":409,"start":410,"enrollment":411,"conditions":412,"interventions":414},"NCT02116036","Rivaroxaban for Antiphospholipid Antibody Syndrome",[79],"2017-09-30","2014-09",81,[413],"Antiphospholipid Antibody Syndrome",[393],{"trials":416,"activeCount":86},[],{"intervention":418,"totalTrials":113,"cells":419},"Mirabegron",{"EARLY_PHASE1":420,"PHASE1":422,"PHASE2":424,"PHASE3":426,"PHASE4":428,"NA":442},{"trials":421,"activeCount":86},[],{"trials":423,"activeCount":86},[],{"trials":425,"activeCount":86},[],{"trials":427,"activeCount":86},[],{"trials":429,"activeCount":86},[430],{"nctId":431,"briefTitle":432,"status":305,"phases":433,"primaryCompletion":434,"completion":434,"start":435,"enrollment":436,"conditions":437,"interventions":440},"NCT02279615","Efficacy And Safety Of Combination Therapy For Treatment Of Overactive Bladder In Male Patients With Benign Prostatic Hyperplasia.",[79],"2022-12","2021-12",200,[438,439],"Overactive Bladder","Benign Prostatic Hyperplasia",[418,441],"Tamsulosin",{"trials":443,"activeCount":86},[],{"intervention":441,"totalTrials":113,"cells":445},{"EARLY_PHASE1":446,"PHASE1":448,"PHASE2":450,"PHASE3":452,"PHASE4":454,"NA":460},{"trials":447,"activeCount":86},[],{"trials":449,"activeCount":86},[],{"trials":451,"activeCount":86},[],{"trials":453,"activeCount":86},[],{"trials":455,"activeCount":86},[456],{"nctId":431,"briefTitle":432,"status":305,"phases":457,"primaryCompletion":434,"completion":434,"start":435,"enrollment":436,"conditions":458,"interventions":459},[79],[438,439],[418,441],{"trials":461,"activeCount":86},[],{"intervention":463,"totalTrials":113,"cells":464},"Bisacodyl 10mg",{"EARLY_PHASE1":465,"PHASE1":467,"PHASE2":469,"PHASE3":471,"PHASE4":473,"NA":486},{"trials":466,"activeCount":86},[],{"trials":468,"activeCount":86},[],{"trials":470,"activeCount":86},[],{"trials":472,"activeCount":86},[],{"trials":474,"activeCount":86},[475],{"nctId":476,"briefTitle":477,"status":305,"phases":478,"primaryCompletion":479,"completion":479,"start":480,"enrollment":141,"conditions":481,"interventions":483},"NCT01627171","Colonoscopy Preparation Optimization for INpatients- COIN Study",[79],"2013-12","2012-09",[369,482],"Bowel Preparation Solutions",[463,484,485],"Polyethelene Glycol","Picosulfate sodium",{"trials":487,"activeCount":86},[],{"intervention":484,"totalTrials":113,"cells":489},{"EARLY_PHASE1":490,"PHASE1":492,"PHASE2":494,"PHASE3":496,"PHASE4":498,"NA":504},{"trials":491,"activeCount":86},[],{"trials":493,"activeCount":86},[],{"trials":495,"activeCount":86},[],{"trials":497,"activeCount":86},[],{"trials":499,"activeCount":86},[500],{"nctId":476,"briefTitle":477,"status":305,"phases":501,"primaryCompletion":479,"completion":479,"start":480,"enrollment":141,"conditions":502,"interventions":503},[79],[369,482],[463,484,485],{"trials":505,"activeCount":86},[],{"intervention":485,"totalTrials":113,"cells":507},{"EARLY_PHASE1":508,"PHASE1":510,"PHASE2":512,"PHASE3":514,"PHASE4":516,"NA":522},{"trials":509,"activeCount":86},[],{"trials":511,"activeCount":86},[],{"trials":513,"activeCount":86},[],{"trials":515,"activeCount":86},[],{"trials":517,"activeCount":86},[518],{"nctId":476,"briefTitle":477,"status":305,"phases":519,"primaryCompletion":479,"completion":479,"start":480,"enrollment":141,"conditions":520,"interventions":521},[79],[369,482],[463,484,485],{"trials":523,"activeCount":86},[],{"intervention":525,"totalTrials":235,"cells":526},"Phytonadione",{"EARLY_PHASE1":527,"PHASE1":529,"PHASE2":531,"PHASE3":533,"PHASE4":557,"NA":559},{"trials":528,"activeCount":86},[],{"trials":530,"activeCount":86},[],{"trials":532,"activeCount":86},[],{"trials":534,"activeCount":86},[535,547],{"nctId":536,"briefTitle":537,"status":105,"phases":538,"primaryCompletion":539,"completion":539,"start":540,"enrollment":541,"conditions":542,"interventions":546},"NCT00990158","Does Low Dose Oral Vitamin K Improve International Normalized Ratio (INR) Stability?",[78],"2014-04","2010-07",235,[543,544,545],"Coagulation","Bleeding","Thrombosis",[525],{"nctId":548,"briefTitle":549,"status":105,"phases":550,"primaryCompletion":551,"completion":552,"start":553,"enrollment":554,"conditions":555,"interventions":556},"NCT00143715","Oral Vitamin K for Warfarin Associated Coagulopathy",[78],"2006-10","2007-01","2004-09",690,[543,544,545],[525],{"trials":558,"activeCount":86},[],{"trials":560,"activeCount":86},[],{"intervention":562,"totalTrials":113,"cells":563},"Sirolimus",{"EARLY_PHASE1":564,"PHASE1":566,"PHASE2":568,"PHASE3":570,"PHASE4":582,"NA":584},{"trials":565,"activeCount":86},[],{"trials":567,"activeCount":86},[],{"trials":569,"activeCount":86},[],{"trials":571,"activeCount":86},[572],{"nctId":573,"briefTitle":574,"status":244,"phases":575,"primaryCompletion":576,"completion":576,"start":577,"enrollment":86,"conditions":578,"interventions":580},"NCT00922129","Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer",[77,78],"2011-01","2009-09",[579],"Prostate Cancer",[562,581],"Cyclosporin",{"trials":583,"activeCount":86},[],{"trials":585,"activeCount":86},[],{"intervention":581,"totalTrials":113,"cells":587},{"EARLY_PHASE1":588,"PHASE1":590,"PHASE2":592,"PHASE3":594,"PHASE4":600,"NA":602},{"trials":589,"activeCount":86},[],{"trials":591,"activeCount":86},[],{"trials":593,"activeCount":86},[],{"trials":595,"activeCount":86},[596],{"nctId":573,"briefTitle":574,"status":244,"phases":597,"primaryCompletion":576,"completion":576,"start":577,"enrollment":86,"conditions":598,"interventions":599},[77,78],[579],[562,581],{"trials":601,"activeCount":86},[],{"trials":603,"activeCount":86},[],{"intervention":605,"totalTrials":113,"cells":606},"Dexamethasone 4mg",{"EARLY_PHASE1":607,"PHASE1":609,"PHASE2":611,"PHASE3":613,"PHASE4":625,"NA":627},{"trials":608,"activeCount":86},[],{"trials":610,"activeCount":86},[],{"trials":612,"activeCount":86},[],{"trials":614,"activeCount":86},[615],{"nctId":616,"briefTitle":617,"status":105,"phases":618,"primaryCompletion":619,"completion":619,"start":620,"enrollment":621,"conditions":622,"interventions":624},"NCT05456542","Cuff Leak Test and Airway Obstruction in Mechanically Ventilated ICU Patients",[78],"2025-01-06","2023-04-05",100,[623],"Respiratory Failure",[605],{"trials":626,"activeCount":86},[],{"trials":628,"activeCount":86},[],{"intervention":630,"totalTrials":113,"cells":631},"Apo-Hydroxychloroquine",{"EARLY_PHASE1":632,"PHASE1":634,"PHASE2":636,"PHASE3":638,"PHASE4":651,"NA":653},{"trials":633,"activeCount":86},[],{"trials":635,"activeCount":86},[],{"trials":637,"activeCount":86},[],{"trials":639,"activeCount":86},[640],{"nctId":641,"briefTitle":642,"status":244,"phases":643,"primaryCompletion":644,"completion":645,"start":646,"enrollment":86,"conditions":647,"interventions":649},"NCT04371523","Hydroxychloroquine to Prevent COVID-19 Disease Amongst Healthcare Workers",[78],"2020-07-31","2020-08-30","2020-05-01",[648],"Corona Virus Infection",[630,650],"Matched Placebo",{"trials":652,"activeCount":86},[],{"trials":654,"activeCount":86},[],{"intervention":650,"totalTrials":113,"cells":656},{"EARLY_PHASE1":657,"PHASE1":659,"PHASE2":661,"PHASE3":663,"PHASE4":669,"NA":671},{"trials":658,"activeCount":86},[],{"trials":660,"activeCount":86},[],{"trials":662,"activeCount":86},[],{"trials":664,"activeCount":86},[665],{"nctId":641,"briefTitle":642,"status":244,"phases":666,"primaryCompletion":644,"completion":645,"start":646,"enrollment":86,"conditions":667,"interventions":668},[78],[648],[630,650],{"trials":670,"activeCount":86},[],{"trials":672,"activeCount":86},[],{"intervention":674,"totalTrials":113,"cells":675},"Bioimpedance and Vitamin D",{"EARLY_PHASE1":676,"PHASE1":678,"PHASE2":680,"PHASE3":695,"PHASE4":697,"NA":699},{"trials":677,"activeCount":86},[],{"trials":679,"activeCount":86},[],{"trials":681,"activeCount":86},[682],{"nctId":683,"briefTitle":684,"status":105,"phases":685,"primaryCompletion":686,"completion":687,"start":688,"enrollment":689,"conditions":690,"interventions":692},"NCT01045980","Assessment of Bioimpedance and Vitamin D and LV Mass in PD Patients (FLUID Study)",[77],"2016-05-15","2016-11-30","2010-08-01",74,[691],"Disorders Associated With Peritoneal Dialysis",[674,693,694],"Usual care and placebo","Usual care and Vitamin D",{"trials":696,"activeCount":86},[],{"trials":698,"activeCount":86},[],{"trials":700,"activeCount":86},[],{"intervention":693,"totalTrials":113,"cells":702},{"EARLY_PHASE1":703,"PHASE1":705,"PHASE2":707,"PHASE3":713,"PHASE4":715,"NA":717},{"trials":704,"activeCount":86},[],{"trials":706,"activeCount":86},[],{"trials":708,"activeCount":86},[709],{"nctId":683,"briefTitle":684,"status":105,"phases":710,"primaryCompletion":686,"completion":687,"start":688,"enrollment":689,"conditions":711,"interventions":712},[77],[691],[674,693,694],{"trials":714,"activeCount":86},[],{"trials":716,"activeCount":86},[],{"trials":718,"activeCount":86},[],{"intervention":694,"totalTrials":113,"cells":720},{"EARLY_PHASE1":721,"PHASE1":723,"PHASE2":725,"PHASE3":731,"PHASE4":733,"NA":735},{"trials":722,"activeCount":86},[],{"trials":724,"activeCount":86},[],{"trials":726,"activeCount":86},[727],{"nctId":683,"briefTitle":684,"status":105,"phases":728,"primaryCompletion":686,"completion":687,"start":688,"enrollment":689,"conditions":729,"interventions":730},[77],[691],[674,693,694],{"trials":732,"activeCount":86},[],{"trials":734,"activeCount":86},[],{"trials":736,"activeCount":86},[],{"intervention":738,"totalTrials":113,"cells":739},"Bupivacaine 0.5% with 1:200 000 epinephrine",{"EARLY_PHASE1":740,"PHASE1":742,"PHASE2":744,"PHASE3":760,"PHASE4":762,"NA":764},{"trials":741,"activeCount":86},[],{"trials":743,"activeCount":86},[],{"trials":745,"activeCount":86},[746],{"nctId":747,"briefTitle":748,"status":305,"phases":749,"primaryCompletion":750,"completion":751,"start":752,"enrollment":753,"conditions":754,"interventions":758},"NCT04427904","Bupivacaine Versus Lidocaine Infiltration for Postoperative Pain in Thyroid Surgery",[77],"2024-12-31","2025-12-31","2022-06-01",210,[755,756,757],"Postoperative Pain","Thyroid Diseases","Anesthesia, Local",[738,759],"Lidocaine 2% with 1:100 000 epinephrine",{"trials":761,"activeCount":86},[],{"trials":763,"activeCount":86},[],{"trials":765,"activeCount":86},[],{"intervention":759,"totalTrials":113,"cells":767},{"EARLY_PHASE1":768,"PHASE1":770,"PHASE2":772,"PHASE3":778,"PHASE4":780,"NA":782},{"trials":769,"activeCount":86},[],{"trials":771,"activeCount":86},[],{"trials":773,"activeCount":86},[774],{"nctId":747,"briefTitle":748,"status":305,"phases":775,"primaryCompletion":750,"completion":751,"start":752,"enrollment":753,"conditions":776,"interventions":777},[77],[755,756,757],[738,759],{"trials":779,"activeCount":86},[],{"trials":781,"activeCount":86},[],{"trials":783,"activeCount":86},[],{"intervention":785,"totalTrials":113,"cells":786},"25:1 CBD\u002FTHC",{"EARLY_PHASE1":787,"PHASE1":789,"PHASE2":791,"PHASE3":807,"PHASE4":809,"NA":811},{"trials":788,"activeCount":86},[],{"trials":790,"activeCount":86},[],{"trials":792,"activeCount":86},[793],{"nctId":794,"briefTitle":795,"status":105,"phases":796,"primaryCompletion":797,"completion":797,"start":798,"enrollment":799,"conditions":800,"interventions":805},"NCT05041647","Cannabinoids as a Treatment for Insomnia in Major Depression",[77],"2025-01-31","2023-08-28",14,[801,802,803,18,804],"Insomnia","Depressive Disorder, Major","Sleep Disorder","Insomnia Chronic",[785,806],"5:1 CBD\u002FTHC",{"trials":808,"activeCount":86},[],{"trials":810,"activeCount":86},[],{"trials":812,"activeCount":86},[],{"intervention":806,"totalTrials":113,"cells":814},{"EARLY_PHASE1":815,"PHASE1":817,"PHASE2":819,"PHASE3":825,"PHASE4":827,"NA":829},{"trials":816,"activeCount":86},[],{"trials":818,"activeCount":86},[],{"trials":820,"activeCount":86},[821],{"nctId":794,"briefTitle":795,"status":105,"phases":822,"primaryCompletion":797,"completion":797,"start":798,"enrollment":799,"conditions":823,"interventions":824},[77],[801,802,803,18,804],[785,806],{"trials":826,"activeCount":86},[],{"trials":828,"activeCount":86},[],{"trials":830,"activeCount":86},[],{"intervention":832,"totalTrials":113,"cells":833},"NK1 Antagonist",{"EARLY_PHASE1":834,"PHASE1":836,"PHASE2":838,"PHASE3":851,"PHASE4":853,"NA":855},{"trials":835,"activeCount":86},[],{"trials":837,"activeCount":86},[],{"trials":839,"activeCount":86},[840],{"nctId":841,"briefTitle":842,"status":305,"phases":843,"primaryCompletion":844,"completion":845,"start":846,"enrollment":847,"conditions":848,"interventions":850},"NCT02989779","Neurokinin (NK) 1 Antagonist for Pathological Aggression for Harmful, Impulsive, and Self-\u002FAggressive Behaviour",[76,77],"2020-03","2020-06","2017-01",50,[849],"Aggression",[832],{"trials":852,"activeCount":86},[],{"trials":854,"activeCount":86},[],{"trials":856,"activeCount":86},[],{"intervention":858,"totalTrials":113,"cells":859},"Yaz",{"EARLY_PHASE1":860,"PHASE1":862,"PHASE2":864,"PHASE3":877,"PHASE4":879,"NA":881},{"trials":861,"activeCount":86},[],{"trials":863,"activeCount":86},[],{"trials":865,"activeCount":86},[866],{"nctId":867,"briefTitle":868,"status":105,"phases":869,"primaryCompletion":870,"completion":870,"start":871,"enrollment":872,"conditions":873,"interventions":876},"NCT05098574","Oral Contraceptives for Treating Premenstrual Dysphoric Disorder in Bipolar Disorder",[77],"2024-04-11","2023-02-03",17,[874,875],"Premenstrual Dysphoric Disorder","Bipolar Disorder",[858],{"trials":878,"activeCount":86},[],{"trials":880,"activeCount":86},[],{"trials":882,"activeCount":86},[],{"intervention":884,"totalTrials":113,"cells":885},"SB-240563",{"EARLY_PHASE1":886,"PHASE1":888,"PHASE2":890,"PHASE3":902,"PHASE4":904,"NA":906},{"trials":887,"activeCount":86},[],{"trials":889,"activeCount":86},[],{"trials":891,"activeCount":86},[892],{"nctId":893,"briefTitle":894,"status":105,"phases":895,"primaryCompletion":896,"completion":897,"start":898,"enrollment":899,"conditions":900,"interventions":901},"NCT00292877","The Prednisone-sparing Effect of Anti-IL-5 Antibody (SB-240563)",[77],"2008-06","2008-07","2005-01",20,[28],[884],{"trials":903,"activeCount":86},[],{"trials":905,"activeCount":86},[],{"trials":907,"activeCount":86},[],{"intervention":909,"totalTrials":113,"cells":910},"Breathe Anew Survivorship Program",{"EARLY_PHASE1":911,"PHASE1":913,"PHASE2":923,"PHASE3":925,"PHASE4":927,"NA":929},{"trials":912,"activeCount":86},[],{"trials":914,"activeCount":86},[915],{"nctId":916,"briefTitle":917,"status":105,"phases":918,"primaryCompletion":919,"completion":919,"start":920,"enrollment":847,"conditions":921,"interventions":922},"NCT03773380","Breathe Anew for Lung Cancer Survivorship",[76],"2022-01-01","2019-01-02",[15],[909],{"trials":924,"activeCount":86},[],{"trials":926,"activeCount":86},[],{"trials":928,"activeCount":86},[],{"trials":930,"activeCount":86},[],{"intervention":932,"totalTrials":113,"cells":933},"18F-DCFPyL",{"EARLY_PHASE1":934,"PHASE1":945,"PHASE2":947,"PHASE3":949,"PHASE4":951,"NA":953},{"trials":935,"activeCount":86},[936],{"nctId":937,"briefTitle":938,"status":305,"phases":939,"primaryCompletion":940,"completion":940,"start":941,"enrollment":942,"conditions":943,"interventions":944},"NCT02691169","Integrated 18F-labelled PSMA Project",[75],"2017-12","2016-04",10,[579],[932],{"trials":946,"activeCount":86},[],{"trials":948,"activeCount":86},[],{"trials":950,"activeCount":86},[],{"trials":952,"activeCount":86},[],{"trials":954,"activeCount":86},[],{"intervention":956,"totalTrials":113,"cells":957},"GeneSight Psychotropic",{"EARLY_PHASE1":958,"PHASE1":960,"PHASE2":962,"PHASE3":964,"PHASE4":966,"NA":968},{"trials":959,"activeCount":86},[],{"trials":961,"activeCount":86},[],{"trials":963,"activeCount":86},[],{"trials":965,"activeCount":86},[],{"trials":967,"activeCount":86},[],{"trials":969,"activeCount":86},[970],{"nctId":971,"briefTitle":972,"status":105,"phases":973,"primaryCompletion":974,"completion":975,"start":976,"enrollment":977,"conditions":978,"interventions":981},"NCT02573168","Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment With Antipsychotics",[80],"2019-07","2020-09","2016-01",103,[979,980],"Schizophrenia","Schizoaffective Disorder",[956,982],"Enhanced-GeneSight Psychotropic",{"intervention":982,"totalTrials":113,"cells":984},{"EARLY_PHASE1":985,"PHASE1":987,"PHASE2":989,"PHASE3":991,"PHASE4":993,"NA":995},{"trials":986,"activeCount":86},[],{"trials":988,"activeCount":86},[],{"trials":990,"activeCount":86},[],{"trials":992,"activeCount":86},[],{"trials":994,"activeCount":86},[],{"trials":996,"activeCount":86},[997],{"nctId":971,"briefTitle":972,"status":105,"phases":998,"primaryCompletion":974,"completion":975,"start":976,"enrollment":977,"conditions":999,"interventions":1000},[80],[979,980],[956,982],{"intervention":1002,"totalTrials":113,"cells":1003},"Antibiotics",{"EARLY_PHASE1":1004,"PHASE1":1006,"PHASE2":1008,"PHASE3":1010,"PHASE4":1012,"NA":1014},{"trials":1005,"activeCount":86},[],{"trials":1007,"activeCount":86},[],{"trials":1009,"activeCount":86},[],{"trials":1011,"activeCount":86},[],{"trials":1013,"activeCount":86},[],{"trials":1015,"activeCount":86},[1016],{"nctId":1017,"briefTitle":1018,"status":305,"phases":1019,"primaryCompletion":435,"completion":435,"start":1020,"enrollment":342,"conditions":1021,"interventions":1023},"NCT04301869","Oral Versus Intravenous Antibiotics for the Treatment of Pleural Space Infection: a Randomized Controlled Pilot Trial",[80],"2020-05",[1022],"Pleural Infection",[1002],{"intervention":1025,"totalTrials":113,"cells":1026},"Cholecalciferol",{"EARLY_PHASE1":1027,"PHASE1":1029,"PHASE2":1031,"PHASE3":1033,"PHASE4":1035,"NA":1037},{"trials":1028,"activeCount":86},[],{"trials":1030,"activeCount":86},[],{"trials":1032,"activeCount":86},[],{"trials":1034,"activeCount":86},[],{"trials":1036,"activeCount":86},[],{"trials":1038,"activeCount":86},[1039],{"nctId":1040,"briefTitle":1041,"status":105,"phases":1042,"primaryCompletion":1043,"completion":1044,"start":576,"enrollment":899,"conditions":1045,"interventions":1048},"NCT01214928","Hemodialysis Vitamin D Pilot",[80],"2011-05","2011-06",[1046,1047],"Vitamin D Deficiency","Renal Failure Chronic Requiring Hemodialysis",[1025],{"intervention":1050,"totalTrials":113,"cells":1051},"Da Vinci Vessel Sealer Extend Energy Device with SureForm Stapling",{"EARLY_PHASE1":1052,"PHASE1":1054,"PHASE2":1056,"PHASE3":1058,"PHASE4":1060,"NA":1062},{"trials":1053,"activeCount":86},[],{"trials":1055,"activeCount":86},[],{"trials":1057,"activeCount":86},[],{"trials":1059,"activeCount":86},[],{"trials":1061,"activeCount":86},[],{"trials":1063,"activeCount":86},[1064],{"nctId":1065,"briefTitle":1066,"status":105,"phases":1067,"primaryCompletion":1068,"completion":1068,"start":1069,"enrollment":1070,"conditions":1071,"interventions":1074},"NCT05727735","Signia Stapler Versus Vessel Sealer Extend Energy Device With SureForm Stapling in Robotic-Assisted Segmentectomy",[80],"2024-04-30","2023-04-14",56,[15,1072,1073],"Thoracic Cancer","Lung Neoplasm",[1050],{"intervention":1076,"totalTrials":113,"cells":1077},"Tinzaparin",{"EARLY_PHASE1":1078,"PHASE1":1080,"PHASE2":1082,"PHASE3":1084,"PHASE4":1086,"NA":1088},{"trials":1079,"activeCount":86},[],{"trials":1081,"activeCount":86},[],{"trials":1083,"activeCount":86},[],{"trials":1085,"activeCount":86},[],{"trials":1087,"activeCount":86},[],{"trials":1089,"activeCount":86},[1090],{"nctId":1091,"briefTitle":1092,"status":1093,"phases":1094,"primaryCompletion":1095,"completion":1096,"start":1097,"enrollment":1098,"conditions":1099,"interventions":1102},"NCT00186745","Use of Low Molecular Weight Heparin (Tinzaparin) to Treat Blood Clots in Patients With Kidney Failure","TERMINATED",[80],"2015-11","2016-02","2005-03",148,[1100,1101],"Venous Thrombosis","Pulmonary Embolism",[1076],{"intervention":1104,"totalTrials":113,"cells":1105},"Zinc Supplement",{"EARLY_PHASE1":1106,"PHASE1":1108,"PHASE2":1110,"PHASE3":1112,"PHASE4":1114,"NA":1116},{"trials":1107,"activeCount":86},[],{"trials":1109,"activeCount":86},[],{"trials":1111,"activeCount":86},[],{"trials":1113,"activeCount":86},[],{"trials":1115,"activeCount":86},[],{"trials":1117,"activeCount":86},[1118],{"nctId":1119,"briefTitle":1120,"status":305,"phases":1121,"primaryCompletion":365,"completion":1122,"start":1123,"enrollment":342,"conditions":1124,"interventions":1127},"NCT01546805","Testing the Effect of Zinc Supplementation to Improve the Treatment Effect of Botulinum Toxin for Oculofacial Spasm",[80],"2013-03","2012-04",[1125,1126],"Blepharospasm","Hemifacial Spasm",[1104,1128],"Sugar pill",{"intervention":1128,"totalTrials":113,"cells":1130},{"EARLY_PHASE1":1131,"PHASE1":1133,"PHASE2":1135,"PHASE3":1137,"PHASE4":1139,"NA":1141},{"trials":1132,"activeCount":86},[],{"trials":1134,"activeCount":86},[],{"trials":1136,"activeCount":86},[],{"trials":1138,"activeCount":86},[],{"trials":1140,"activeCount":86},[],{"trials":1142,"activeCount":86},[1143],{"nctId":1119,"briefTitle":1120,"status":305,"phases":1144,"primaryCompletion":365,"completion":1122,"start":1123,"enrollment":342,"conditions":1145,"interventions":1146},[80],[1125,1126],[1104,1128],{"intervention":1148,"totalTrials":113,"cells":1149},"Venlafaxine",{"EARLY_PHASE1":1150,"PHASE1":1152,"PHASE2":1154,"PHASE3":1156,"PHASE4":1158,"NA":1160},{"trials":1151,"activeCount":86},[],{"trials":1153,"activeCount":86},[],{"trials":1155,"activeCount":86},[],{"trials":1157,"activeCount":86},[],{"trials":1159,"activeCount":86},[],{"trials":1161,"activeCount":86},[1162],{"nctId":1163,"briefTitle":1164,"status":305,"phases":1165,"primaryCompletion":1166,"completion":1167,"start":1168,"enrollment":1169,"conditions":1170,"interventions":1171},"NCT01369290","Electroencephalography (EEG) Signal Processing",[],"2012-10","2013-10","2009-10",150,[30],[1148,1172,1173,1174],"bupropion","escitalopram","Duloxetine",{"intervention":1172,"totalTrials":113,"cells":1176},{"EARLY_PHASE1":1177,"PHASE1":1179,"PHASE2":1181,"PHASE3":1183,"PHASE4":1185,"NA":1187},{"trials":1178,"activeCount":86},[],{"trials":1180,"activeCount":86},[],{"trials":1182,"activeCount":86},[],{"trials":1184,"activeCount":86},[],{"trials":1186,"activeCount":86},[],{"trials":1188,"activeCount":86},[1189],{"nctId":1163,"briefTitle":1164,"status":305,"phases":1190,"primaryCompletion":1166,"completion":1167,"start":1168,"enrollment":1169,"conditions":1191,"interventions":1192},[],[30],[1148,1172,1173,1174],{"intervention":1173,"totalTrials":113,"cells":1194},{"EARLY_PHASE1":1195,"PHASE1":1197,"PHASE2":1199,"PHASE3":1201,"PHASE4":1203,"NA":1205},{"trials":1196,"activeCount":86},[],{"trials":1198,"activeCount":86},[],{"trials":1200,"activeCount":86},[],{"trials":1202,"activeCount":86},[],{"trials":1204,"activeCount":86},[],{"trials":1206,"activeCount":86},[1207],{"nctId":1163,"briefTitle":1164,"status":305,"phases":1208,"primaryCompletion":1166,"completion":1167,"start":1168,"enrollment":1169,"conditions":1209,"interventions":1210},[],[30],[1148,1172,1173,1174],{"intervention":1174,"totalTrials":113,"cells":1212},{"EARLY_PHASE1":1213,"PHASE1":1215,"PHASE2":1217,"PHASE3":1219,"PHASE4":1221,"NA":1223},{"trials":1214,"activeCount":86},[],{"trials":1216,"activeCount":86},[],{"trials":1218,"activeCount":86},[],{"trials":1220,"activeCount":86},[],{"trials":1222,"activeCount":86},[],{"trials":1224,"activeCount":86},[1225],{"nctId":1163,"briefTitle":1164,"status":305,"phases":1226,"primaryCompletion":1166,"completion":1167,"start":1168,"enrollment":1169,"conditions":1227,"interventions":1228},[],[30],[1148,1172,1173,1174],{"intervention":1230,"totalTrials":113,"cells":1231},"everolimus",{"EARLY_PHASE1":1232,"PHASE1":1234,"PHASE2":1236,"PHASE3":1238,"PHASE4":1240,"NA":1242},{"trials":1233,"activeCount":86},[],{"trials":1235,"activeCount":86},[],{"trials":1237,"activeCount":86},[],{"trials":1239,"activeCount":86},[],{"trials":1241,"activeCount":86},[],{"trials":1243,"activeCount":86},[1244],{"nctId":1245,"briefTitle":1246,"status":105,"phases":1247,"primaryCompletion":1248,"completion":1248,"start":1249,"enrollment":899,"conditions":1250,"interventions":1252},"NCT01107509","Pilot Study of Neo-Adjuvant Everolimus to Treat Advanced Renal Cell Carcinoma - Analysis of Biomarkers",[80],"2017-10-01","2010-10-01",[1251],"Carcinoma, Renal Cell",[1230],{"intervention":1254,"totalTrials":113,"cells":1255},"Temsirolimus",{"EARLY_PHASE1":1256,"PHASE1":1258,"PHASE2":1260,"PHASE3":1262,"PHASE4":1264,"NA":1266},{"trials":1257,"activeCount":86},[],{"trials":1259,"activeCount":86},[],{"trials":1261,"activeCount":86},[],{"trials":1263,"activeCount":86},[],{"trials":1265,"activeCount":86},[],{"trials":1267,"activeCount":86},[1268],{"nctId":1269,"briefTitle":1270,"status":105,"phases":1271,"primaryCompletion":1272,"completion":1272,"start":1273,"enrollment":1274,"conditions":1275,"interventions":1277},"NCT01404104","Neo-adjuvant Temsirolimus in Patients With Advanced Renal Cell Carcinoma",[80],"2014-08","2008-09",11,[1276],"Renal Cell Carcinoma",[1254]]